What this means
This study will give some older adults a compound called fisetin and others a fake pill, then compare lung function. The trial is still recruiting, so it does not show whether fisetin works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 60 and over · 40 older adults aged 60 and up, some smokers and some never-smokers
- Where
- 1 site, including California
The science
- Registered title
- Ongoing Lung Decline With Age Intensified Response
- Trial ID
- NCT07676435 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Age-Related Lung Function Decline
- What is tested
- Fisetin, Placebo
- Sponsor
- Cedars-Sinai Medical Center
- Ages
- 60 Years to no maximum
- Dates
- First posted Jun 30, 2026 · updated Oct 15, 2026
Registry summary
This Phase II, randomized, double-blind, placebo-controlled pilot study will evaluate the effects of fisetin, a senolytic flavonoid compound, on lung function and biomarkers of cellular senescence in older adults aged 60 years and older. Participants will include individuals with a history of at least 10 pack-years of smoking as well as age-matched never-smokers. Forty participants will be randomized to receive either fisetin or placebo using a short-course "hit-and-run" dosing strategy (approximately 20 mg/kg/day orally for 2 consecutive days on Days 1-2 and Days 8-9).
Sites (1)
- Cedars-Sinai Medical Center, Los Angeles, California, United States